- Open Access
IL-9-triggered lncRNA Gm13568 regulates Notch1 in astrocytes through interaction with CBP/P300: contribute to the pathogenesis of experimental autoimmune encephalomyelitis
Journal of Neuroinflammation volume 18, Article number: 108 (2021)
Interleukin 9 (IL-9), produced mainly by T helper 9 (Th9) cells, has been recognized as an important regulator in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). Astrocytes respond to IL-9 and reactive astrocytes always associate with blood-brain barrier damage, immune cell infiltration, and spinal injury in MS and EAE. Several long non-coding RNAs (lncRNAs) with aberrant expression have been identified in the pathogenesis of MS. Here, we examined the effects of lncRNA Gm13568 (a co-upregulated lncRNA both in EAE mice and in mouse primary astrocytes activated by IL-9) on the activation of astrocytes and the process of EAE.
In vitro, shRNA-recombinant lentivirus with glial fibrillary acidic protein (GFAP) promoter were performed to determine the relative gene expression and proinflammatory cytokines production in IL-9 treated-astrocytes using Western blot, real-time PCR, and Cytometric Bead Array, respectively. RIP and ChIP assays were analyzed for the mechanism of lncRNA Gm13568 regulating gene expression. Immunofluorescence assays was performed to measure the protein expression in astrocytes. In vivo, H&E staining and LFB staining were applied to detect the inflammatory cells infiltrations and the medullary sheath damage in spinal cords of EAE mice infected by the recombinant lentivirus. Results were analyzed by one-way ANOVA or Student’s t test, as appropriate.
Knockdown of the endogenous lncRNA Gm13568 remarkably inhibits the Notch1 expression, astrocytosis, and the phosphorylation of signal transducer and activator of transcription 3 (p-STAT3) as well as the production of inflammatory cytokines and chemokines (IL-6, TNF-α, IP-10) in IL-9-activated astrocytes, in which Gm13568 associates with the transcriptional co-activators CBP/P300 which are enriched in the promoter of Notch1 genes. More importantly, inhibiting Gm13568 with lentiviral vector in astrocytes ameliorates significantly inflammation and demyelination in EAE mice, therefore delaying the EAE process.
These findings uncover that Gm13568 regulates the production of inflammatory cytokines in active astrocytes and affects the pathogenesis of EAE through the Notch1/STAT3 pathway. LncRNA Gm13568 may be a promising target for treating MS and demyelinating diseases.
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS), in which immune cells infiltrate into the white matter associated with demyelination and axonal loss . The occupancy of T cells and glia cells in patient lesions suggests that both are important contributors to MS [2, 3]. Autoreactive effector CD4+T cells, including proinflammatory Th1 cell and Th17 cell, are believed to be the major effector cells , which migrate into the CNS and initiate the MS process. Recently, Th9 cell and its secreting cytokine IL-9 have been implicated in MS, which activates and cooperates with other CD4+T cells and CNS-resident cells in MS and experimental autoimmune encephalomyelitis (EAE), an animal model of MS .
Astrocytes, the most abundant cell population in the CNS, play an essential role in the homeostasis of CNS. Astrocytes participate in the formation and integrity of the blood-brain barrier (BBB), support of neurons, and regulation of axonal outgrowth. When CNS injury occurs, astrocytes become activated, which are clearly identified by the dramatically upregulated expression of glial fibrillary acidic protein (GFAP) [6, 7]. In response to IL-9 stimulation, astrocytes aggravate the BBB disruption, increase chemokine production and facilitate T cell migration into the CNS [8, 9]. However, the mechanisms by which astrocyte activation with IL-9 stimulation contribute to MS remains undefined.
The Notch signaling is a fundamental and well-conserved pathway associated with cell fate. The canonical Notch pathway arises from the interaction of transmembrane Notch receptors (Notch1- 4) with ligands (Jagged1, Jagged2, DLL1, DLL3 or DLL4), whereas the non-canonical pathway is activated through various molecules, such as NF-κB, STAT3 [10, 11]. Upon ligand binding or activation, Notch1 is cleaved and releases Notch1 intracellular domain (NICD) that directly translocates into the nucleus to form a complex with RBP/J and mastermind like (MAML) proteins, which promotes the transcription of target genes [10, 11]. In addition, NICD binds to the serine residue of phosphorylated STAT3 (p-STAT3), facilitates the nuclear translocation of p-STAT3, and initiates the transcription of corresponding target genes [12, 13]. It has been reported that Notch is associated with several progressive neurodegenerative diseases, including MS, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). Notch1 signaling activation increases astrocyte proliferation and enhances reactive astrogliosis after CNS injury [14, 15].
Long noncoding RNAs (lncRNAs), ranging from hundreds to tens of thousands of nucleotides in length with no protein-coding capacity, have been proved to play vital roles in diverse biological processes of genomic imprinting and development to immune response . LncRNAs are involved in neurodegenerative diseases, including MS, ALS, AD, Parkinson’s disease (PD), and Huntington’s disease (HD) [17, 18]. Importantly, differentially expressed-lncRNAs in activated astrocytes are closely related to EAE progression . However, the mechanisms underlying how lncRNAs regulate astrocytes activation and MS process are still poorly understood.
The transcriptional co-activators CREB-binding protein (CBP) and P300 are histone acetyltransferase (HAT) contributing to histone 3 lysine 27 acetylation (H3K27ac), RNA Pol II acetylation, and NF-κB enrichment in the promoter region of target genes, which forms a transcription network to facilitate the expression of target gene [20,21,22,23,24]. Lately, it has been reported that CBP/P300 binds directly to RNA to enhance histone acetylation and gene transcription . Additionally, lncRNAs are associated with the CBP/p300 complex and RNA polymerase II, which regulate gene expression [24, 26].
In previous study, we analyzed lncRNA expression profiles in EAE mice as well as in activated astrocytes with IL-9 stimulation . Here, we aim to further explore the function and mechanism of lncRNA Gm13568 (a co-upregulated lncRNA in EAE mice and IL-9-activated astrocytes) in regulating astrocytes activation and EAE progression. We display that Gm13568 contributes to the production of inflammatory cytokines and chemokines in activated astrocytes through interaction with CBP/P300, which is enriched in the promoter of Notch1 and promotes Notch1 expression and signaling activation, thereby aggravating the EAE damage. These results suggest that targeting lncRNAs in astrocytes is an attractive option for the treatment of MS.
Animal, antibodies, and reagents
C57BL/6 mice were purchased from the Shanghai Experimental Animal Center, Chinese Academy of Sciences. All experimental procedures described in our study were carried out based on the Provision and General Recommendation of the Chinese Laboratory Association. The protocol was approved by the Laboratory Animal Ethics Committee of Xuzhou Medical University (201801w005). All mice we bred under specific pathogen-free conditions. Antibodies used in this study were as follows: anti-IL-9 antibody (Rabbit, ab203386, Abcam), anti-GFAP antibody (Rabbit, ab7260, Abcam), anti-GFAP (Mouse, ab4648, Abcam), anti-cleaved Notch1 antibody (NICD, Rabbit, 4147, Cell Signaling Technology), anti-Notch 1 antibody (Goat, sc-6014, SANTA CRUZ), anti-p-STAT3 (Rabbit, Tyr705, BS4181, Bioworld Technology), anti-STAT3 (Rabbit, AP0365, Bioworld Technology), NF-κB p65 (Rabbit, 8242, Cell Signaling Technology), anti- CBP/P300 antibody (Rabbit, 4771s, Cell Signaling Technology), anti-RNA Pol II antibody (Mouse, 17-620, Sigma Aldrich), and anti-H3K27ac antibody (Rabbit, ab177178, Abcam). The secondary antibodies were all purchased from Sigma Biotechnology. Myelin oligodendrocyte glycoprotein (MOG) amino acids 35-55 (MOG35-55 peptides, MEVGWYRSPFSRVVHLYRNGK) were purchased from China Peptides Co. Ltd (shanghai, China). Recombinant mouse IL-9 was from R&D Systems; multiplex magnetic bead-based antibody detection kits (cytokine and chemokine detection kits, Cytometric Bead Array) were from BD Biosciences.
EAE induction and clinical evaluation
C57BL/6 female mice (6–8 weeks old) were immunized with 250 μg MOG35-55 emulsified in complete Freund’s adjuvant (Sigma Aldrich) containing 5 mg/ml heat-killed Mycobacterium tuberculosis (H37Ra strain, Difco). On day 0 and day 2, mice were intraperitoneally received pertussis toxin (200 ng, Invitrogen), and then mice were monitored daily for clinical signs of EAE according to the following grading scale in a double-blinded manner: 0, no clinical signs; 1, limp tail; 2, paraparesis (weakness, incomplete paralysis of one or two hind limbs); 3, paraplegia (two hind limbs paralysis); 4, paraplegia with fore limb weakness or paralysis; and 5, moribund or death. The PBS with the same volume was injected into mice as the negative control.
Primary astrocyte culture
Primary mouse astrocytes were separated and cultured as described previously . Astrocytes were synchronized with non-serum culture media for 12 h before IL-9 stimulation.
Real-time PCR assay
Total RNA from the spinal cords of mouse or astrocytes was extracted by Trizol reagent (Invitrogen). Real-time PCR assay was conducted as described previously . The relative genes transcription was calculated with the 2−ΔΔCT method. The primers are listed in Supplementary Table S1.
Cytometric Bead Array (CBA) assay
The serum of mice or the supernatant of cultured astrocytes was collected. The secretion levels of IL-6, TNF-α, interferon-inducible protein-10 (IP-10), and monocyte chemoattractant protein-1 (MCP-1) were detected by CBA assay (BD Biosciences, USA) as described previously .
Western blot assay
As described previously , the total protein was extracted from the spinal cords of mouse as well as the cultured astrocytes. The expression level of protein in samples was normalized by β-actin protein.
Recombinant lentiviral vectors carrying EGFP and astrocyte-specific promoter of glial fibrillary acidic protein (GFAP) were constructed by Gene Chem (Shanghai, China) and were verified (Supplementary Fig. S1). Because the sequence of Gm13568 completely complements the sense chain at the 9075-9497 locus of the Notch1 gene, conventional shRNA knockdown may simultaneously affect the expression of endogenous Notch1 gene. We constructed recombinant lentivirus vectors with GFAP promoter that overexpresses the 9075-9497 sequence of Notch1 gene to make them competitively bind to Gm13568 (LV-Inhibit-Gm13568), so as to inhibit the effect of endogenous Gm13568 on Notch1 expression.
RNA Immunoprecipitation (RIP) assay
RIP assay was performed as previously described . In brief, after treating with IL-9, 2 × 107 primary mouse astrocytes were treated with 0.3% formaldehyde in culture medium, and then 0.125 M Glycine was added to the medium. Cells were washed in cold PBS and pelleted. The pellets were resuspended in RIPA buffer and incubated on ice, and the lysate was centrifugated at 13,000 RPM for 10 min. Antibodies mixing Protein A/G beads were added and incubated at 4 °C overnight. Next, the beads were resuspended in RIPA buffer and were treated with proteinase K at 45 °C for 45 min. Finally, samples were extracted with Trizol and then RNA was detected by real-time PCR assay. The data of retrieved RNAs were calculated by the subtraction of RT/input ratio and non-RT/input ratio. The primer sequence of Gm13568 was listed in Supplementary Table S1.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed as described previously . Primary mouse astrocytes were treated with IL-9 for 6 h. 1 × 107 cells were used for each ChIP-enrichment. Chromatin was sheared to the fragment size of 200–500 bp. The antibodies were anti-NF-κB p65, anti-H3K27ac, anti-RNA Pol II, anti-CBP/P300, and normal mouse IgG. All immunoprecipitated chromatin DNA was analyzed by real-time PCR. The primer sequences were listed in Supplementary Table S1.
Histopathology assay was performed as previously described [27, 31]. Hematoxylin and eosin (H&E) or luxol fast blue (LFB) staining on 4 μm paraffin-embedded spinal cord sections were used in evaluating inflammation and demyelination, respectively.
Statistical analysis was performed by GraphPad Prism version 5.0 software with the two-tailed unpaired Student's t test or one-way multiple-range analysis of variance (ANOVA). A Mann-Whitney test was used for nonparametric data (EAE scoring). Data presented as mean ± standard error of mean (SEM), calculated for all points from at least three independent experiments in triplicates. Values of p < 0.05 was considered significant.
The production of IL-9 and inflammatory cytokines as well as the expression of NICD and p-STAT3 are increased in EAE mice
It has been recently demonstrated that Th9/IL-9 is a key player in regulating autoimmune responses in MS and EAE accompanied by the production of a large number of inflammatory cytokines. To investigate the potential role of IL-9 in inducing Notch1 pathway activation, reactive astrogliosis, and the production of inflammatory cytokines in EAE mice, we firstly measured the expression of IL-9 in the tissues of spinal cords. As shown in Fig. 1a, the mRNA and protein level of IL-9 was gradually increased in the spinal cords along with the severity of EAE. Then, the expression of GFAP, NICD, and p-STAT3 was detected by Western blot assay. The results showed that the expression of GFAP protein was markedly elevated in the spinal cords of EAE mice with score 2.0 and lasted until score 4.0. Similarly, the expression of NICD and the phosphorylation level of STAT3 (p-STAT3) was also significantly upregulated from EAE score 2.0 to score 4.0 (Fig. 1b). Finally, the mRNA transcription and secretion of pro-inflammatory cytokines and chemokines (IL-6, TNF-α, IP-10, and MCP-1) in the spinal cords and peripheral blood of EAE mice were assessed by real-time PCR and CBA assay, respectively (Fig. 1c, d). The production of IL-6, TNF-α, IP-10, and MCP-1 was obviously increased along with EAE process, which was consistent with our previous study . These results suggest whether IL-9 secreted by Th cells stimulates astrogliosis and Notch1 signal activation, therefore promoting the production of pro-inflammatory cytokines and chemokines in the CNS of EAE mice.
IL-9 stimulates astrocytes to promote Notch1 pathway activation and inflammatory cytokine production
To explore the role of IL-9 in Notch1 pathway activation and inflammatory cytokine production in astrocytes, primary mouse astrocytes were treated with IL-9 in serum-free media. Western blot results showed that the expression of GFAP was dramatically increased at 6 h and lasted for 24 h in the astrocytes with IL-9 treatment. Meanwhile, the expressions of NICD and p-STAT3 were elevated at 6 h after IL-9 stimulation (Fig. 2a). The results of an immunofluorescence assay indicated that the expression of Notch1 in cytoplasm was also significantly increased in IL-9 stimulated-astrocytes, compared to the DMEM group (Fig. 2b). In addition, the mRNA transcription and secretion levels of inflammatory cytokines such as IL-6, TNF-α, IP-10, and MCP-1 were simultaneously upregulated and peaked at 6 h in the astrocytes stimulated by IL-9 (Fig. 2c, d). These data suggest that IL-9 activates the Notch1/ STAT3 signaling pathway and promotes the productions of pro-inflammatory cytokines in astrocytes.
Knockdown of Notch1 suppresses inflammatory response in astrocytes by IL-9
To further investigate whether Notch1 is involved in regulating inflammatory responses in IL-9 stimulated-astrocytes, recombinant lentiviral vectors of three Notch1-shRNA (LV-Notch1-shRNA) specifically targeting astrocytes were constructed and transfected into primary mouse astrocytes, respectively. As shown in Fig. 3a, the Notch1 protein level was significantly repressed in Notch1-shRNA-1, shRNA-2, and shRNA-3 groups, particularly in the shRNA-3 group, compared with the shRNA-ctrl group. Thus, the recombinant lentiviral vector of Notch1-shRNA-3 was selected for packaging and infection. Western blot results showed that the expression of NICD and the phosphorylation level of STAT3 were obviously decreased from LV-Notch1-shRNA infection group in IL-9 treated-astrocytes, compared to the LV-ctrl group (Fig. 3b). Furthermore, the production of inflammatory cytokines including IL-6, TNF-α, and IP-10 was markedly reduced in LV-Notch1-shRNA infected-astrocytes (Fig. 3c, d). These results indicate that IL-9-induced upregulation and activation of Notch1 contribute to the inflammatory cytokines production in astrocytes.
Identification of lncRNA Gm13568 targeting Notch1
In our previous study, the changes of lncRNA profiles were reported both in EAE mice (in vivo) and in activated astrocytes with IL-9 stimulation (in vitro) . We further found that the sequence of ENSMUST00000156099 (Gm13568, one of the lncRNA co-upregulated in vivo and in vitro) with 446 bp length is identical to the antisense sequence of Notch1 gene at the 9075-9497 locus that is complementary to the sense chain of the Notch1 gene (located between exon 2 and exon 3) (Fig. 4a, b). The time course data showed that the changes of mRNA level between Gm13568 and Notch1 mirrored one another. At 3 h of IL-9 treatment, the levels of Gm13568 and Notch1 were significantly increased and lasted for 12 h (Fig. 4c). Taken together, these results suggest that Gm13568 may have a positive regulatory effect on Notch1 expression.
LncRNA Gm13568 regulates the Notch1 pathway and inflammatory cytokine production in activated astrocytes by IL-9
To evaluate the role of Gm13568 in regulating Notch1 expression and signal activation and inflammatory cytokines production in activated astrocytes, we infected primary mouse astrocytes with recombinant lentivirus inhibiting Gm13568 (LV-Inhibit Gm13568) that we had constructed and packaged. In the LV-Inhibit-Gm13568 group, the expressions of GFAP and Notch1were lower after IL-9 stimulation for 6 h than that of LV-ctrl group, indicating the inhibition of Gm13568 significantly decreased the Notch1 expression and reactive astrocytosis (Fig. 5a). Similarly, the expression of NICD and p-STAT3 were also markedly decreased in LV-Inhibit-Gm13568 group (Fig. 5a). Additionally, the production of IL-6, TNF-α and IP-10 was in much lower level in the LV-Inhibit-Gm13568 group (Fig. 5b, c). These observations indicate that Gm13568 regulates the expression and signal activation of Notch1, therefore mediating the production of inflammatory cytokines in astrocytes.
The interaction of Gm13568 with CBP/P300 regulates the Notch1 expression in astrocytes by IL-9
To further explore the potential regulating mechanism of Gm13568 on Notch1 expression, the RIP assay was performed to analyze Gm13568 and NF-κB p65 or CBP/P300 interaction. As shown in Fig. 6a, Gm13568 was significantly interacted with NF-κB p65 and CBP/P300 in activated astrocytes by IL-9. Moreover, ChIP assay revealed that NF-κB p65, CBP/P300, RNA Pol II, and H3K27ac were differentially enriched in the Notch1 gene promoter in IL-9-activated astrocytes (Fig. 6b). Importantly, inhibition of Gm13568 significantly reduced NF-κB p65 and CBP/P300 enrichment in the Notch1 promoter (Fig. 6c). The data indicate that the interaction of Gm13568 with CBP/P300 may epigenetically regulate the transcription of the Notch1 gene.
Notch1 knockdown in astrocytes represses inflammation and alleviates EAE in mice
To further clarify the role of Notch1 from astrocytes in EAE development, 1 × 107 transforming units of recombinant lentivirus of LV-Notch1-shRNA specifically targeting astrocytes was injected into mice via the tail vein. After 7 days, EAE was induced by MOG 35-55 for 23 days. The clinical score showed that silencing Notch1 in astrocytes not only delayed the onset of EAE but also relieved illness (Fig. 7a). Meanwhile, the production of IL-9 and the expression of GFAP were significantly decreased in EAE mice with LV-Notch1-shRNA (Fig. 7b). Furthermore, NICD and p-STAT3 protein expressions were also markedly downregulated in the spinal cords of the LV-Notch1-shRNA group (Fig. 7b). The levels of inflammatory cytokines such as IL-6, TNF-α and IP-10 were reduced in LV-Notch1-shRNA group (Fig. 7c, d). More importantly, H&E and LFB staining strongly displayed that LV-ctrl EAE mice had greater inflammatory cell infiltration and more severe demyelination lesions in the spinal cords. However, the EAE mice with LV-Notch1-shRNA had less inflammatory cell infiltration and slight demyelination lesions in the spinal cords (Fig. 7e, f). Collectively, these data reveal that Notch1 participants in the activation and hyperplasia of astrocytes, resulting in aggravation of inflammatory cell infiltration and spinal cords injury in EAE mice, which may be associated with an increased inflammatory reaction. On the contrary, knockdown of Notch1 reversed these results above.
The inhibition of Gm13568 in astrocytes decreases the activation of the Notch1 pathway and ameliorates the EAE process in mice
To verify whether Gm13568 regulating Notch1 in astrocytes contributes to the development of EAE, 1 × 107 transforming units of recombinant lentivirus targeting astrocytes (LV-Inhibit-Gm13568 or LV-ctrl) was administrated to mice via the tail vein, and then EAE was induced after 7 days. As shown in Fig. 8a, inhibiting Gm13568 in astrocytes slowed down the EAE development. At the same time, the production of IL-9 was significantly reduced compared to the LV-ctrl mice (Fig. 8b). The expressions of GFAP, Notch1, NICD, and p-STAT3 were dramatically decreased in the LV-Inhibit-Gm13568 mice (Fig. 8b). Similarly, the production of IL-6, TNF-α, and IP-10 was also markedly diminished in LV-Inhibit-Gm13568 group (Fig. 8c, d). In addition, H&E and LFB staining showed that inflammatory cell infiltration and demyelination lesions in white matter were obviously reduced in LV-Inhibit-Gm13568 group, compared to the LV-ctrl mice (Fig. 8e, f). Taken together, these data imply that the lncRNA Gm13568 regulates the Notch1 pathway in astrocytes, thus controlling reactive astrocytosis, inflammatory cytokine secretion and spinal cord injury in mice, in turn affecting the EAE process.
Astrocytes play important roles in MS by recruiting lymphocytes, confining inflammation and contributing to tissue damage [31, 32]. It has also been reported that lncRNAs have significant impacts on normal neural development and the progression of neurodegenerative diseases . Our previous studies have demonstrated that lncRNAs differentially expressed in the activated astrocytes are closely related to EAE process . Here, we confirm that inhibiting lncRNA Gm13568, an upregulated lncRNA both in IL-9-activated astrocytes and in EAE mice, reduces inflammatory cytokine production in astrocytes and delays the EAE process through decreasing Notch1 expression and signal activation by interaction with NF-κB p65 and CBP/P300 (Fig. 9).
In CNS autoimmunity, reactive astrocytes can contribute to a detrimental positive-feedback loop of inflammation, which accelerates inflammatory cascades and aggravates neurological disorders . Response to inflammatory stress, many genes relevant to inflammation, oxidative stress, immune receptors, and BBB disruption are increased in astrocytes . It has been shown that astrocytes aggravate BBB disruption, increase chemokines production, and facilitate T cell migration to the CNS upon IL-9 stimulation [8, 9]. Our data showed that mRNA transcription and protein expression of IL-9 in the spinal cords of EAE mice were gradually increased along with the severity of EAE. Notably, the expression of GFAP and the secretion of pro-inflammatory cytokines were also significantly upregulated along with the severity of EAE, which implied the activation and hyperplasia of reactive astrocytes. However, the understanding of the role of IL-9 in promoting astrogliosis is still very limited.
The Notch pathway can modulate immune response and inflammatory processes, which are clinically critical in MS. Emerging evidence indicates the Notch signal regulates the development and maturation of microglia, oligodendrocytes, and CD4+T cells in MS lesions, which are associated with MS pathology . Inhibiting the Notch1 pathway in oligodendrocytes improved remyelination in EAE mice and in the cuprizone (CPZ) demyelination model [34, 35]. It has been demonstrated that Notch-1 signaling is a critical regulator of intracerebral hemorrhage (ICH)-induced reactive astrogliosis . Our results showed that the expression of Notch1, NICD, and p-STAT3 was consistent with that of GFAP and inflammation cytokines production in EAE and in reactive astrocytes with IL-9 stimulation. Importantly, knockdown Notch1 in astrocytes not only decreased inflammatory production both in vivo and in vitro, but also reduced inflammatory cell infiltration and demyelination lesion in the spinal cords of EAE mice. Yet, the underlying mechanisms behind Notch1 modulation in astrocytes are far from clear in MS.
In recent years, lncRNAs having been shown to play vital roles in diverse biological processes ranging from development to immune responses. In the CNS, they diversely participate in neuroinflammation, synapse plasticity, synaptogenesis, and memory formation [30, 36, 37]. Accumulating evidence has indicated that lncRNAs are key regulatory molecules involved in MS pathogenesis [38,39,40,41,42], but these data mainly focused on the regulation of Th cells and microglia by lncRNAs. Given that astrocytes play essential roles in MS process, it is crucial to understand the role of lncRNAs in astrocytes in MS. To date, the functional characterization of lncRNAs during astrocyte activation and MS process has not been fully uncovered. Our previous study identified the changes of lncRNA expression profiles both in EAE mice and in activated astrocytes with IL-9 stimulation . We found that the sequence of co-upregulated lncRNA Gm13568 in vivo and in vitro were complementary to the 9075-9497 locus of the sense chain in the Notch1 gene, and the time course of Gm13568 changes was consistent with that of Notch 1 in IL-9-stimulated astrocytes. lncRNAs are known to control the expression of genes as well as contribute to the pathogeneses of diseases. Therefore, we propose that Gm13568 may positively regulate the expression of Notch1 gene in astrocytes, therefore contributing to the EAE pathogeneses. In this study, our data supports this hypothesis. Our study revealed that the inhibition of Gm13568 decreased Notch1 expression and pathway activation in astrocytes, as well as attenuated reactive astrocytosis both in vitro and in vivo, which elicited the reduction of inflammatory cytokines and chemokines production, thus alleviating inflammatory cell infiltration and demyelination lesion in EAE mice. However, it is still not very clear about the mechanisms by which lncRNAs act on Notch1in astrocytes.
It has been demonstrated that lncRNAs can modulate protein-coding gene expression in chromatin remodeling and histone modification, which are always associated with the CBP/p300 complex, the CoREST/REST complex and the Polycomb Repressive Complex 2 (PRC2) complex [16, 36]. In the present study, RIP and ChIP assay showed that Gm13568 associated with NF-κB p65 and CBP/P300 was enriched in the promoter of Notch1gene. These data suggest that the interaction of Gm13568 and CBP/P300 might epigenetically regulate Notch1 expression in activated astrocytes and EAE mice.
In summary, our present evidence reveals that lncRNA Gm13568 induced by IL-9 in astrocytes regulates Notch1 expression through the interaction with CBP/P300 and then promotes Notch1 pathway activation, which is involved in the production of inflammatory cytokines and chemokines in astrocytes, in turn affecting EAE development. Thus, these findings emphasize that the lncRNA derives from astrocytes may play key roles in neuroinflammation and pathogenesis of MS.
Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary information files.
CREB-binding protein (CBP) and p300
Experimental autoimmune encephalomyelitis
Signal transducer and activator of transcription 3
Tumor necrosis factor-α
Interferon-gamma induced protein 10
Monocyte chemoattractant protein-1
The central nervous system
Glial fibrillary acidic protein
Notch1 intracellular domain
Myelin oligodendrocyte glycoprotein
Cytometric Bead Array
Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019;1812:905–22.
Dong Y, Yong VW. When encephalitogenic T cells collaborate with microglia in multiple sclerosis. Nat Rev Neurol. 2019;1512:704–17.
Yi W, Schlüter D, Wang X. Astrocytes in multiple sclerosis and experimental autoimmune encephalomyelitis: star-shaped cells illuminating the darkness of CNS autoimmunity. Brain Behav Immun. 2019;80:10–24. https://doi.org/10.1016/j.bbi.2019.05.029.
Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;974:742–68.
Elyaman W, Khoury SJ. Th9 cells in the pathogenesis of EAE and multiple sclerosis. Semin Immunopathol. 2017;391:79–87.
Brambilla R. The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathol. 2019;1375:757–83.
Santello M, Toni N, Volterra A. Astrocyte function from information processing to cognition and cognitive impairment. Nat Neurosci. 2019;222:154–66.
Tan S, Shan Y, Lin Y, Liao S, Zhang B, Zeng Q, et al. Neutralization of interleukin-9 ameliorates experimental stroke by repairing the blood-brain barrier via down-regulation of astrocyte-derived vascular endothelial growth factor-A. Faseb J. 2019;333:4376–87.
Zhou Y, Sonobe Y, Akahori T, Jin S, Kawanokuchi J, Noda M, et al. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol. 1867;2011:4415–21.
Arumugam TV, Baik SH, Balaganapathy P, Sobey CG, Mattson MP, Jo DG. Notch signaling and neuronal death in stroke. Prog Neurobiol. 2018;165-167:103–16.
Pagie S, Gérard N, Charreau B. Notch signaling triggered via the ligand DLL4 impedes M2 macrophage differentiation and promotes their apoptosis. Cell Commun Signal. 2018;161:4.
Nonneman A, Criem N, Lewandowski SA, Nuyts R, Thal DR, Pfrieger FW, et al. Astrocyte-derived Jagged-1 mitigates deleterious Notch signaling in amyotrophic lateral sclerosis. Neurobiol Dis. 2018;119:26–40. https://doi.org/10.1016/j.nbd.2018.07.012.
Bhoopathi P, Chetty C, Dontula R, Gujrati M, Dinh DH, Rao JS, et al. SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1/STAT3 pathway. Cancer Res. 2011;7114:4908–19.
Ho DM, Artavanis-Tsakonas S, Louvi A. The Notch pathway in CNS homeostasis and neurodegeneration. Wiley Interdiscip Rev Dev Biol. 2020;91:e358.
Zhong JH, Zhou HJ, Tang T, Cui HJ, Yang AL, Zhang QM, et al. Activation of the Notch-1 signaling pathway may be involved in intracerebral hemorrhage-induced reactive astrogliosis in rats. J Neurosurg. 2018;1293:732–9.
Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;1723:393–407.
Wan P, Su W, Zhuo Y. The role of long noncoding RNAs in neurodegenerative diseases. Mol Neurobiol. 2017;543:2012–21.
Zhang F, Gao C, Ma XF, Peng XL, Zhang RX, Kong DX, et al. Expression profile of long noncoding RNAs in peripheral blood mononuclear cells from multiple sclerosis patients. CNS Neurosci Ther. 2016;224:298–305.
Liu X, Zhang Q, Wang W, Zuo D, Wang J, Zhou F, et al. Analysis of long noncoding RNA and mRNA expression profiles in IL-9-activated astrocytes and EAE mice. Cell Physiol Biochem. 2018;455:1986–98.
Dutto I, Scalera C, Prosperi E. CREBBP and p300 lysine acetyl transferases in the DNA damage response. Cell Mol Life Sci. 2018;758:1325–38.
Schröder S, Herker E, Itzen F, He D, Thomas S, Gilchrist DA, et al. Acetylation of RNA polymerase II regulates growth-factor-induced gene transcription in mammalian cells. Mol Cell. 2013;523:314–24.
Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE, et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27 ac in nuclear receptor transactivation. Embo J. 2011;302:249–62.
Dyson HJ, Wright PE. Role of intrinsic protein disorder in the function and interactions of the transcriptional coactivators CREB-binding protein (CBP) and p300. J Biol Chem. 2016;29113:6714–22.
Verhoeven RJA, Tong S, Mok BW, Liu J, He S, Zong J, et al. Epstein-Barr virus BART long non-coding RNAs function as epigenetic modulators in nasopharyngeal carcinoma. Front Oncol. 2019;9:1120. https://doi.org/10.3389/fonc.2019.01120.
Bose DA, Donahue G, Reinberg D, Shiekhattar R, Bonasio R, Berger SL. RNA binding to CBP stimulates histone acetylation and transcription. Cell. 2017;1681-2:135–149.e122.
Cui W, Yoneda R, Ueda N, Kurokawa R. Arginine methylation of translocated in liposarcoma (TLS) inhibits its binding to long noncoding RNA, abrogating TLS-mediated repression of CBP/p300 activity. J Biol Chem. 2018;29328:10937–48.
Liu X, He F, Pang R, Zhao D, Qiu W, Shan K, et al. Interleukin-17 (IL-17)-induced microRNA 873 (miR-873) contributes to the pathogenesis of experimental autoimmune encephalomyelitis by targeting A20 ubiquitin-editing enzyme. J Biol Chem. 2014;28942:28971–86.
Gao J, Kang XY, Sun S, Li L, Zhang BL, Li YQ, et al. Transcription factor Six2 mediates the protection of GDNF on 6-OHDA lesioned dopaminergic neurons by regulating Smurf1 expression. Cell Death Dis. 2016;75:e2217.
Zhou F, Liu X, Gao L, Zhou X, Cao Q, Niu L, et al. HIV-1 Tat enhances purinergic P2Y4 receptor signaling to mediate inflammatory cytokine production and neuronal damage via PI3K/Akt and ERK MAPK pathways. J Neuroinflammation. 2019;161:71.
Zhou F, Liu X, Zuo D, Xue M, Gao L, Yang Y, et al. HIV-1 Nef-induced lncRNA AK006025 regulates CXCL9/10/11 cluster gene expression in astrocytes through interaction with CBP/P300. J Neuroinflammation. 2018;151:303.
Liu X, Zhou F, Yang Y, Wang W, Niu L, Zuo D, et al. MiR-409-3p and MiR-1896 co-operatively participate in IL-17-induced inflammatory cytokine production in astrocytes and pathogenesis of EAE mice via targeting SOCS3/STAT3 signaling. Glia. 2019;671:101–12.
Ponath G, Park C, Pitt D. The role of astrocytes in multiple sclerosis. Front Immunol. 2018;9:217. https://doi.org/10.3389/fimmu.2018.00217.
Wang X, Mulas F, Yi W, Brunn A, Nishanth G, Just S, et al. OTUB1 inhibits CNS autoimmunity by preventing IFN-γ-induced hyperactivation of astrocytes. EMBO J. 2019;38(10):e100947.
Bassil R, Orent W, Elyaman W. Notch signaling and T-helper cells in EAE/MS. Clin Dev Immunol. 2013;2013:570731.
Fan H, Zhao JG, Yan JQ, Du GQ, Fu QZ, Shi J, et al. Effect of Notch1 gene on remyelination in multiple sclerosis in mouse models of acute demyelination. J Cell Biochem. 2018;11911:9284–94.
Hosseini E, Bagheri-Hosseinabadi Z, De Toma I, Jafarisani M, Sadeghi I. The importance of long non-coding RNAs in neuropsychiatric disorders. Mol Aspects Med. 2019;70:127–40. https://doi.org/10.1016/j.mam.2019.07.004.
Cortini F, Roma F, Villa C. Emerging roles of long non-coding RNAs in the pathogenesis of Alzheimer’s disease. Ageing Res Rev. 2019;50:19–26. https://doi.org/10.1016/j.arr.2019.01.001.
Sun D, Yu Z, Fang X, Liu M, Pu Y, Shao Q, et al. LncRNA GAS5 inhibits microglial M2 polarization and exacerbates demyelination. EMBO Rep. 2017;1810:1801–16.
Zhang F, Liu G, Wei C, Gao C, Hao J. Linc-MAF-4 regulates Th1/Th2 differentiation and is associated with the pathogenesis of multiple sclerosis by targeting MAF. Faseb J. 2017;312:519–25.
Yang X, Wu Y, Zhang B, Ni B. Noncoding RNAs in multiple sclerosis. Clin Epigenetics. 2018;101:149.
Ghoveud E, Teimuri S, Vatandoost J, Hosseini A, Ghaedi K, Etemadifar M, et al. Potential biomarker and therapeutic LncRNAs in multiple sclerosis through targeting memory B cells. Neuromolecular Med. 2020;221:111–20.
Ghaiad HR, Elmazny AN, Nooh MM, El-Sawalhi MM, Shaheen AA. Long noncoding RNAs APOA1-AS, IFNG-AS1, RMRP and their related biomolecules in Egyptian patients with relapsing-remitting multiple sclerosis: relation to disease activity and patient disability. J Adv Res. 2020;21:141–50. https://doi.org/10.1016/j.jare.2019.10.012.
We would like to thank the professors Kuiyang Zheng and Renxian Tang from the Jiangsu Key Laboratory of Immunity and Metabolism.
This work was supported by the National Natural Science Foundation of China (81971179 to Liu, 82071304 and 81671149 to Zhang, 81702027 to Yu, 81461138036 to Sun), the Natural Science Foundation of Jiangsu Province (BK20191463 to Liu), Jiangsu Commission of Health (Z2019035 to Zhou), Jiangsu Provincial Department of Education (20KJA320004 to Zhou), the Priority Academic Program Development of Jiangsu Higher Education Institutions (2017 PAPD), and Xuzhou Medical Young Talents Project and Xuzhou Technology Bureau Foundation (KC17115, KC16SS081, KC19167 to Zhang).
Ethics approval and consent to participate
Experimental procedures were approved by the Institutional Animal Use Committee of the Shanghai Institutes for Biological Sciences (Chinese Academy of Sciences) and the Ethical Committee for Xuzhou Medical University.
Consent for publication
None of the authors have any conflicts of interest in this study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The neurons and astrocytes were infected by lentivirus with GFAP promoter. The HT-22 cell strain of mouse hippocampal neuron and primary mouse astrocytes were infected by the lentivirus with the astrocyte-specific promoter of GFAP or GFP (without GFAP promoter). At 72 h after lentivirus infection, GFAP or GFP expression were observed under fluorescence scope (Scale bars, 50 μm).
The list of primer sequences for qPCR assay.
About this article
Cite this article
Liu, X., Zhou, F., Wang, W. et al. IL-9-triggered lncRNA Gm13568 regulates Notch1 in astrocytes through interaction with CBP/P300: contribute to the pathogenesis of experimental autoimmune encephalomyelitis. J Neuroinflammation 18, 108 (2021). https://doi.org/10.1186/s12974-021-02156-5
- LncRNA Gm13568
- Inflammatory cytokines
- Experimental autoimmune encephalomyelitis (EAE)